BASF agrees enzymes research, license deal with US Dyadic

15 May 2013 14:56  [Source: ICIS news]

LONDON (ICIS)--Germany’s BASF has agreed a non-exclusive worldwide research and license agreement for enzymes with US-based biotechnology firm Dyadic International, the companies said on Wednesday.

Under the deal, BASF will use Dyadic's patented and proprietary C1 fungus platform technology to develop, produce, distribute and sell industrial enzymes for a variety of applications, they said in a joint statement.

BASF will fund research and development at Dyadic's research lab in the Netherlands.

In addition, BASF agreed to pay Dyadic a $6m (€4.6m) upfront license fee, certain research and commercial milestone fees, as well as royalties upon commercialisation.

BASF said that the cooperation with Dyadic would strengthen its position in the industrial enzyme industry.

According to information on Dyadic’s website, the company’s C1 fungus enables development and large-scale production of low-cost enzymes and other proteins.

($1 = €0.77)


By: Stefan Baumgarten
+1 713 525 2653



AddThis Social Bookmark Button

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly